(Q33538427)

27 July 2017

1 reference

title

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients (English)

1 reference

27 July 2017

1 reference

Michelino De Laurentiis

1 reference

ORCID Public Data File 2021

author name string

De Placido S

1

1 reference

27 July 2017

Carlomagno C

2

1 reference

27 July 2017

De Laurentiis M

3

1 reference

27 July 2017

Bianco AR

4

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

Breast Cancer Research and Treatment

27 July 2017

published in

1 reference

27 July 2017

volume

52

1 reference

27 July 2017

issue

1-3

1 reference

27 July 2017

page(s)

55-64

1 reference

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

The type 1 (EGFR-related) family of growth factor receptors and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Steroid hormone receptor phosphorylation: is there a physiological role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Cell biological factors associated with the response of breast cancer to systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Action of "pure" antiestrogens in inhibiting estrogen receptor action

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006159001039

7 January 2021

Identifiers

DOI

10.1023/A:1006159001039

1 reference

Dimensions Publication ID

27 July 2017

1052898044

0 references

1 reference